Clinical Trial Update: Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) for Glypican-3 positive unresectable hepatocellular carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• RYZ801
• RYZ811

Snippet

Sponsor: RayzeBio, Inc. | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: RECRUITING